Vertex Reports Third Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Stifel Positive on Vertex (VRTX) as Triple Combo Moves Forward; PT Trimmed to $108
October 26, 2016 9:22 AM EDTStifel analyst Adam Walsh trimmed his price target on Vertex (NASDAQ: VRTX) to $108.00 (from $109.00) but maintained a Buy rating as the triple combo moves forward.
Walsh commented, "At last, Vertex outlined the path forward for its triple combo regimens, removing an overhang on the stock as the competitive landscape heats up with Galapagos/Abbvie (not... More
Vertex (VRTX) PT Bumped to $88 at BMO Capital Following Results and Triple Combo Update
October 26, 2016 6:51 AM EDTBMO Capital analyst Do Kim bumped his price target on Vertex (NASDAQ: VRTX) to $88.00 (from $87.00) following results and the triple combo update but maintained a Market Perform rating.
Kim commented, " Vertex's 3Q16 was generally in line with expectations, as prior comments and revised... More
Vertex Pharma (VRTX) Misses Q3 EPS by 2c; Plans to Commence Two CF-Focused Phase 2s
October 25, 2016 4:04 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $0.16, $0.02 worse than the analyst estimate of $0.18. Revenue for the quarter came in at $410 million versus the consensus estimate of $418.37 million.
Vertex also announced the planned initiation of two Phase 2 studies to evaluate the next-generation correctors VX-440 and VX-152 in triple combination regimens with tezacaftor (VX-661) and ivacaftor in people with cystic fibrosis (CF). The Phase 2 study of VX-440 is designed to evaluate the safety and efficacy of 4-week dosing of VX-440 in combination with tezacaftor and ivacaftor in approximately 40 people with CF who... More
